

TRANSMITTAL LETTER TO THE UNITED STATES

ISPH-0573

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/869894

INTERNATIONAL APPLICATION NO.
PCT/US99/29593

INTERNATIONAL FILING DATE
14 December 1999

PRIORITY DATE CLAIMED
7 January 1999

TITLE OF INVENTION

Antisense Modulation of Novel Anti-Apoptotic BCL-2-Related Proteins

APPLICANT(S) FOR DO/EO/US

ACKERMANN, Elizabeth J. et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). - **unexecuted**
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with P
20. ☐ A second copy of the published international application under 35 U.S.
21. ☐ A second copy of the English language translation of the international :
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

- 1) Courtesy copy of International Application;
- 2) Written opinion
- 3) Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825.
- 4) Return post card

"Express Mail" Label No. **EL780366205US**
Date of Deposit **July 6, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

U.S. APPLICATION NO. OF KNOWN, SEE 37 CFR

097/869894

ATTORNEY'S DOCKET NUMBER

ISPH-0573

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	41 - 20 =	21	x \$18.00
Independent claims	1 - 3 =	0	x \$80.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$1,238.00

- ☒ Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

\$619.00

SUBTOTAL =

\$619.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$619.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00

TOTAL FEES ENCLOSED =

\$619.00

Applicant, ISIS Pharmaceuticals, Inc. is entitled to small entity status. It is a small business concern.

Amount to be:

refunded

\$

charged

\$

- a. ☐ A check in the amount of _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-1619 in the amount of \$619.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1619. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257
Kathleen A. Tyrrell, Reg. No. 38,350
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

Telephone: (856) 810-1515
Facsimile: (856) 810-1454

SIGNATURE

Kathleen A. Tyrrell

NAME

32,257

REGISTRATION NUMBER

July 6, 2001

DATE

09/869894

JC18 Rec'd PCT/PTO 0 6 JUL 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0573
Inventors: Ackermann et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: Antisense Modulation of Novel Anti-Apoptotic BCL-2 Related Proteins

"Express Mail" Label No. EL 780366205 US
Date of Deposit - July 6, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- () I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- () I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: JULY 6, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

ANTISENSE MODULATION OF NOVEL ANTI-APOPTOTIC
BCL-2-RELATED PROTEINS

FIELD OF THE INVENTION

The present invention provides compositions and methods
5 for modulating the expression of novel anti-apoptotic bcl-2-
related proteins. In particular, this invention relates to
antisense compounds, particularly oligonucleotides,
specifically hybridizable with nucleic acids encoding anti-
apoptotic human bcl-2-related proteins. Such oligonucleotides
10 have been shown to modulate the expression of novel anti-
apoptotic bcl-2-related proteins.

BACKGROUND OF THE INVENTION

Programmed cell death, or apoptosis, is an essential
feature of growth and development, as the control of cell
15 number is a balance between cell proliferation and cell death.
Apoptosis is an active rather than a passive process,
resulting in cell suicide as a result of any of a number of
external or internal signals. Apoptotic cell death is
characterized by nuclear condensation, endonucleolytic
20 degradation of DNA at nucleosomal intervals ("laddering") and
plasma membrane blebbing. Programmed cell death plays an
essential role in, for example, immune system development and
nervous system development. In the former, T cells displaying
autoreactive antigen receptors are removed by apoptosis. In
25 the latter, a significant reshaping of neural structures
occurs, partly through apoptosis.

An increasing number of genes and gene products have
been implicated in apoptosis. One of these is bcl-2, which
is an intracellular membrane protein shown to block or delay
30 apoptosis. Overexpression of bcl-2 has been shown to be

- 2 -

related to hyperplasia, autoimmunity and resistance to apoptosis, including that induced by chemotherapy (Fang et al., *J. Immunol.* 1994, 153, 4388-4398). A family of bcl-2-related genes has been described. All bcl-2 family members share two highly conserved domains, BH1 and BH2. bcl-2 family members include, but are not limited to, A1, mcl-1, bcl-w, bax, bad, bak and bcl-x. A1, mcl-1, bcl-w and bcl-xl (long form of bcl-x) are presently known to confer protection against apoptosis and are referred to herein as "anti-apoptotic bcl-2-related proteins." Of these, A1 and mcl-1 are known as "novel anti-apoptotic bcl-2-related proteins." In contrast, bax, bad, bak and bcl-xs (short form of bcl-x) are presently known to promote cell death by inhibiting this protective effect. The present invention relates to the novel anti-apoptotic human bcl-2-related proteins, particularly human A1 and mcl-1, and inhibition of the expression of these proteins using antisense technology.

The gene encoding A1 (also known as bcl-2-related gene expressed in fetal liver, or bfl-1, and Glasgow Rearranged Sequence, or GRS) was identified as an early response gene in murine hematopoietic cells treated with granulocyte-macrophage colony-stimulating factor. The human homolog was subsequently found to have extensive homology to bcl-2, especially within the BH1 and BH2 domains. A correlation was noted between the expression level of A1 and the development of stomach cancer in clinical samples. Choi et al., 1995, *Oncogene* 11, 1693-1698; WO 96/30513. The coding sequence of human A1 was cloned (Karsan et al., 1996, *Blood* 87, 3089-3096; Genbank accession no. U29680) and found to be expressed by hematopoietic cells but also a variety of nonhematopoietic tissues. A1 is rapidly inducible by phorbol esters and inflammatory cytokines, and possibly by vascular endothelial growth factor. A1 is believed to play a role in the regulation of physiological cell death during embryonic development. Carrio et al., 1996, *Am. J. Path.*, 149, 2133-2142. There is slight variation among

- 3 -

A1 sequences, with the human A1 sequence originally defined as "GRS" differing by two amino acids from the A1 sequence originally defined as "bfl-1". The GRS sequence was originally isolated by NIH3T3 focus formation assay using DNA obtained from a patient with chronic myeloid leukemia. Kenny et al, *Oncogene* 14, 1997 997-1001. These researchers found a high level of A1 expression in the cancer cell lines U-937 (histiocytic lymphoma), HL-60 (promyelocytic leukemia) and Raji (Burkitt lymphoma) cells. Expression of A1 was also found in THP-1 (acute myeloid leukemia), BJAB (Burkitt lymphoma), activated Jurkat (acute T-cell leukemia) cells and K-562 erythroleukemia (CML blast crisis) cells.

mcl-1 was originally identified from the differentiating human myeloid leukemia cell line ML-1. Its expression was found to increase early in the induction or "programming" of differentiation of ML-1 cells before the appearance of differentiation markers. The coding region of mcl-1 was sequenced and found to have a pronounced region of sequence homology to bcl-2 in the carboxyl-terminal region. Kozopas et al., *Proc. Natl. Acad. Sci. USA.*, 1993, 90, 3516-3520; Genbank accession no. L08246. Unlike bcl-2, mcl-1 contains a strong PEST sequence (enriched in proline, glutamic acid, serine and threonine) which is present in a variety of proteins that undergo rapid turnover.

Overexpression of exogenously introduced mcl-1 has been shown to cause a prolongation of viability under conditions that normally cause apoptotic cell death, such as exposure to cytotoxic agents (the chemotherapeutic agent etoposide, calcium ionophore or UV irradiation) or the withdrawal of required growth factors. Zhou et al., *Blood* 89, 1997, 630-643.

Diseases and conditions in which apoptosis has been implicated fall into two categories, those in which there is increased cell survival (i.e., apoptosis is reduced) and those in which there is excess cell death (i.e., apoptosis is

- 4 -

increased). Diseases in which there is an excessive accumulation of cells due to increased cell survival include cancer, autoimmune disorders and viral infections. Until recently, it was thought that cytotoxic drugs killed target cells directly by interfering with some life-maintaining function. However, of late, it has been shown that exposure to several cytotoxic drugs with disparate mechanisms of action induces apoptosis in both malignant and normal cells. Manipulation of levels of trophic factors (e.g., by anti-estrogen compounds or those which reduce levels of various growth hormones) has been one clinical approach to promote apoptosis, since deprivation of trophic factors can induce apoptosis. Apoptosis is also essential for the removal of potentially autoreactive lymphocytes during development and the removal of excess cells after the completion of an immune or inflammatory response. Recent work has clearly demonstrated that improper apoptosis may underlie the pathogenesis of autoimmune diseases by allowing abnormal autoreactive lymphocytes to survive. For these and other conditions in which insufficient apoptosis is believed to be involved, promotion of apoptosis is desired. Inhibition of novel anti-apoptotic bcl-2-related proteins according to the present invention is believed to result in promotion of apoptosis.

In the second category, AIDS and neurodegenerative disorders like Alzheimer's or Parkinson's disease represent disorders for which an excess of cell death due to promotion of apoptosis (or unwanted apoptosis) has been implicated. Amyotrophic lateral sclerosis, retinitis pigmentosa, and epilepsy are other neurologic disorders in which apoptosis has been implicated. Apoptosis has been reported to occur in conditions characterized by ischemia, e.g. myocardial infarction and stroke. Apoptosis has also been implicated in a number of liver disorders including obstructive jaundice and hepatic damage due to toxins and drugs. Apoptosis has also

- 5 -

been identified as a key phenomenon in some diseases of the kidney, i.e. polycystic kidney, as well as in disorders of the pancreas including diabetes (Thatte, et al., *Drugs*, 1997, 54, 511-532). For these and other diseases and conditions in
5 which unwanted apoptosis is believed to be involved, inhibitors of apoptosis are desired.

Antisense oligonucleotides have been used to elucidate the role of several members of the bcl-2 family. Extensive studies using antisense oligonucleotides targeted to bcl-2
10 have been performed, and an antisense compound (G3139, Genta Incorporated) targeted to human bcl-2 has entered clinical trials for lymphoma and prostate cancer.

Amarante-Mendes et al., *Oncogene*, 1998, 16, 1383-1390, disclose antisense oligonucleotides targeted to bcr and bcl-x.
15 The latter downregulated the expression of bcl-xl and increased the susceptibility of HL-60 Bcr-Abl cells to staurosporine.

U.S. Patent 5,583,034 (Green et al.) discloses antisense oligonucleotides which hybridize to the nucleic acid sequence
20 of an anti-apoptotic gene, preferably to the translation start site of bcr-abl.

Wang et al. used a phosphorothioate oligonucleotide targeted to the bcl-x translation start site to block CD40L-mediated apoptotic rescue in murine WEHI-231 lymphoma cells
25 (*J. Immunol.*, 1995, 155, 3722-3725).

Fujio et al. have used an antisense oligodeoxynucleotide targeted to murine and rat bcl-x mRNA to reduce bcl-xl protein expression (*J. Clin. Invest.*, 1997, 99, 2898-2905). The compound tested was the same as that of Wang et al.
30 Oligonucleotide treatment inhibited the cytoprotective effect of leukemia inhibitory factor in mouse or rat cardiac myocytes.

Pollman et al. used antisense oligodeoxynucleotides with phosphorothioate backbones to downregulate bcl-xl expression
35 in blood vessel intimal cells (*Nature Med.*, 1998, 4, 222-227).

- 6 -

This resulted in induction of apoptosis and regression of vascular lesions. Antisense sequences were targeted to the translation initiation codon of mouse/human bcl-x (conserved sequence) and were used in rabbits. Gibbons et al., U.S.

5 Patent 5,776,905, disclose methods for targeted deletion of intimal lesion cells in the vasculature of a mammal with vascular disease, preferably with antisense molecules specific for anti-apoptotic genes, more preferably bcl-x and most preferably bcl-xl.

10 Thompson et al., U.S. Patent 5,646,008 and WO 95/00642 describe an isolated and purified polynucleotide that encodes a polypeptide other than bcl-2 that promotes or inhibits programmed vertebrate cell death. Preferably the polypeptide is bcl-xl, bcl-xs or bcl-x₁. Polypeptides, polynucleotides
15 identical or complementary to a portion of the isolated and purified polynucleotide, expression vectors, host cells, antibodies and therapeutic and diagnostic methods of use are also provided.

Yang et al., WO 98/05777 disclose bcl-xy (gamma), a
20 novel isoform of the bcl-x family which includes an ankyrin domain. Polypeptide and nucleic acid sequences for this isoform are disclosed, as well as, *inter alia*, methods for modulating bcl-xy activity, including antisense methods.

Chao et al., *Molec. Cell. Biol.*, 1998, 18, 4883-4898,
25 used an antisense construct containing the entire human mcl-1 cDNA in antisense orientation to show that down-regulation of endogenous mcl-1 in TF-1 cells can induce apoptosis of these cells.

Cory et al. (WO 97/35971) disclose methods for
30 modulating expression of bcl-w in a mammal by contacting the bcl-w gene with an effective amount of a modulator of bcl-w expression. Both enhanced and decreased bcl-w expression, including use of antisense sequences to bcl-w, are disclosed.

- 7 -

WO 96/30513 (Shin et al.) discloses the sequence of a Bcl-2 related gene, Bfl-1, and use of a Bcl-2 related gene for diagnosing cancer.

WO 94/29330 discloses, inter alia, the mcl-1 polypeptide
5 sequence and polynucleotide sequence, host cells and vectors
containing the latter, antibodies which bind to the mcl-1
polypeptide, and diagnostic and therapeutic methods using
these compounds. Methods for treating a subject with a mcl-1
associated cell proliferative disorder are generally
10 disclosed, including antisense oligonucleotide and ribozyme
approaches. No specific sequence or targeting information is
provided.

SUMMARY OF THE INVENTION

The present invention is directed to antisense
15 compounds, particularly oligonucleotides, which are targeted
to a nucleic acid encoding novel anti-apoptotic bcl-2-related
proteins, and which modulate the expression of these family
members. In preferred embodiments the antisense
oligonucleotides are targeted to human A1 or human mcl-1.
20 Pharmaceutical compositions comprising the antisense compounds
of the invention are also provided. Further provided are
methods of modulating the expression of novel anti-apoptotic
bcl-2-related proteins in cells or tissues comprising
contacting said cells or tissues with one or more of the
25 antisense compounds or compositions of the invention. Methods
for promoting apoptosis in cells or tissues are also provided.
Further provided are methods of treating an animal,
particularly a human, suspected of having or being prone to
a disease or condition associated with expression of novel
30 anti-apoptotic bcl-2-related proteins, or for which an
increase in apoptosis is desired, by administering a
therapeutically or prophylactically effective amount of one
or more of the antisense compounds or compositions of the
invention.

- 8 -

DETAILED DESCRIPTION OF THE INVENTION

The present invention comprehends antisense compounds capable of modulating expression of novel anti-apoptotic bcl-2-related proteins, particularly human A1 and mcl-1. A1 and mcl-1 inhibit apoptosis and therefore inhibitors of these targets are desired as promoters of apoptosis.

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding novel anti-apoptotic bcl-2-related proteins, ultimately modulating the amount of bcl-2-related protein produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding novel anti-apoptotic bcl-2-related proteins. As used herein, the terms "target nucleic acid" and "nucleic acid encoding a novel anti-apoptotic bcl-2-related protein" encompass DNA encoding a novel anti-apoptotic bcl-2-related protein, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of the novel anti-apoptotic bcl-2-related protein. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of

- 9 -

a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding a novel anti-apoptotic bcl-2-related protein. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for

- 10 -

translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to
5 initiate translation of an mRNA molecule transcribed from a gene encoding a novel anti-apoptotic bcl-2-related protein, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of
10 three sequences, *i.e.*, 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about
15 50 contiguous nucleotides in either direction (*i.e.*, 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either
20 direction (*i.e.*, 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination
25 codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the
30 translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation
35 termination codon and 3' end of an mRNA or corresponding

- 11 -

nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding

- 12 -

with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment, and in the case of *in vitro* assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses.

- 13 -

Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical
5 trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an
10 oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-
15 occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence
20 of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The
25 antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). As is known in the
30 art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the
35 sugar portion of the nucleoside. For those nucleosides that

- 14 -

include a pentofuranosyl sugar, the phosphate group can be linked to either the 2'-, 3'- or 5'- hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric structure can be further joined to form a circular structure. However, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

- 15 -

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of

- 16 -

the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)₃-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. Patent 5,489,677, and the amide backbones of the above referenced U.S. Patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂,

- 17 -

and $O(CH_2)_nON[(CH_2)_mCH_3]_2$, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3 , OCN, Cl, Br, CN, CF_3 , OCF_3 , $SOCH_3$, SO_2CH_3 , ONO_2 , NO_2 , N_3 , NH_2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes an alkoxyalkoxy group, 2'-methoxyethoxy (2'-O- $CH_2CH_2OCH_3$, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504). A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE.

Other preferred modifications include 2'-methoxy (2'-O- CH_3), 2'-aminopropoxy (2'-O $CH_2CH_2CH_2NH_2$) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein incorporated by reference.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or

- 18 -

substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Patent 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pp. 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie, International Edition*, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Crooke, S.T., and Lebleu, B. eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 289-302. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more

- 19 -

particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 10 5,614,617; 5,681,941; and 5,750,692, each of which is herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, 15 cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 20 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl 25 residues (Saison-Behmouaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate 30 (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36,

- 20 -

3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxysterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

5 Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 10 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 15 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.

20 It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes 25 antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, 30 i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased 35 binding affinity for the target nucleic acid. An additional

- 21 -

region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of
5 RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques
10 known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such
15 compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065;
20 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for
25 such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the
30 phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized *in vitro* and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the *in vivo* synthesis of antisense molecules.

- 22 -

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 or in WO 94/26764.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the

- 23 -

desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred addition salts are acid salts such as the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid,

- 24 -

hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embolic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid,

- 25 -

naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be
5 utilized for diagnostics, therapeutics, prophylaxis and as
research reagents and kits. For therapeutics, an animal,
preferably a human, suspected of having a disease or disorder
which can be treated by modulating the expression of one or
more novel anti-apoptotic bcl-2-related proteins is treated
10 by administering antisense compounds in accordance with this
invention. The compounds of the invention can be utilized in
pharmaceutical compositions by adding an effective amount of
an antisense compound to a suitable pharmaceutically
acceptable diluent or carrier. Use of the antisense compounds
15 and methods of the invention may also be useful
prophylactically, e.g., to prevent or delay inflammation or
tumor formation, for example.

The antisense compounds of the invention are useful for
research and diagnostics, because these compounds hybridize
20 to nucleic acids encoding novel anti-apoptotic bcl-2-related
proteins, enabling sandwich and other assays to easily be
constructed to exploit this fact. Hybridization of the
antisense oligonucleotides of the invention with a nucleic
acid encoding a novel anti-apoptotic bcl-2-related protein can
25 be detected by means known in the art. Such means may include
conjugation of an enzyme to the oligonucleotide,
radiolabelling of the oligonucleotide or any other suitable
detection means. Kits using such detection means for
detecting the level of novel anti-apoptotic bcl-2-related
30 proteins in a sample may also be prepared.

The present invention also includes pharmaceutical
compositions and formulations which include the antisense
compounds of the invention. The pharmaceutical compositions
of the present invention may be administered in a number of
35 ways depending upon whether local or systemic treatment is

- 26 -

desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including
5 by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular,
10 administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments,
15 lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

20 Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

25 Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other
30 pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions and/or formulations comprising the oligonucleotides of the present invention may also include penetration enhancers in order to enhance the alimentary delivery of the oligonucleotides. Penetration
35 enhancers may be classified as belonging to one of five broad

- 27 -

categories, i.e., fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8, 91-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). One or more penetration enhancers from one or more of these broad categories may be included.

Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (a.k.a. 1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arichidonic acid, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono- and di-glycerides and physiologically acceptable salts thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 91-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7:1, 1-33; El-Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654). Examples of some presently preferred fatty acids are sodium caprate and sodium laurate, used singly or in combination at concentrations of 0.5 to 5%.

The physiological roles of bile include the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, 1996, pages 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. A presently preferred bile salt is chenodeoxycholic acid (CDCA) (Sigma Chemical Company, St. Louis, MO), generally used at concentrations of 0.5 to 2%.

- 28 -

Complex formulations comprising one or more penetration enhancers may be used. For example, bile salts may be used in combination with fatty acids to make complex formulations. Preferred combinations include CDCA combined with sodium caprate or sodium laurate (generally 0.5 to 5%).

Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 92-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7:1, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51). Chelating agents have the added advantage of also serving as DNase inhibitors.

Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 92-191); and perfluorochemical emulsions, such as FC-43 (Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252-257).

Non-surfactants include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 92-191); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

As used herein, "carrier compound" refers to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic

- 29 -

acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioated oligonucleotide in hepatic tissue is reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

In contrast to a carrier compound, a "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The pharmaceutically acceptable carrier may be liquid or solid and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates (e.g., starch, sodium starch glycolate, etc.); or wetting agents (e.g.,

- 30 -

sodium lauryl sulphate, etc.)). Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are described in U.S. Patents 4,704,295; 4,556,552; 4,309,406; and 4,309,404, which are
5 incorporated by reference.

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain
10 additional compatible pharmaceutically-active materials such as, e.g., antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavoring
15 agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the invention.

Regardless of the method by which the antisense
20 compounds of the invention are introduced into a patient, colloidal dispersion systems may be used as delivery vehicles to enhance the *in vivo* stability of the compounds and/or to target the compounds to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not
25 limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterized structure. A preferred colloidal dispersion system is a plurality of
30 liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer layer(s) made up of lipids arranged in a bilayer configuration (see, generally, Chonn et al., *Current Op. Biotech.*, 1995, 6, 698-708).

Certain embodiments of the invention provide for
35 liposomes and other compositions containing (a) one or more

- 31 -

antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pp. 1206-1228. Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pp. 2499-2506 and 46-49, respectively. Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be

- 32 -

calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative
5 potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 μ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20
10 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to
15 prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with
20 specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

25 Nucleoside Phosphoramidites for Oligonucleotide Synthesis

Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham, MA or Glen Research, Inc. Sterling, VA).
30 Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy

- 33 -

amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine
5 (5-Me-C) nucleotides were synthesized according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling, VA or ChemGenes, Needham, MA).

2'-Fluoro amidites

10 2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously by Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841 and U.S. Patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-
15 deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-
20 beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and
25 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and
30 conversion to the intermediate diisobutryryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give

- 34 -

diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced

- 35 -

pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh
5 ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 hours) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt
10 (ca. 5%). The material was used as is for further reactions or purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C.

2'-O-Methoxyethyl-5-methyluridine

15 2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution
20 evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was
25 packed in CH₂Cl₂/Acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure
30 fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue

- 36 -

dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane(4:1). Pure product

- 37 -

fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

5 A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 hours using
10 an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction
15 mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl,
20 dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M)
25 in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with
30 NH₃ gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The

- 38 -

organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

5 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was evaporated and
10 the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane
15 (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

20 N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture
25 was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄ and
30 concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (3:1) as the eluting

- 39 -

solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

2'-O-(dimethylaminoxyethyl) nucleoside amidites

2'-(Dimethylaminoxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminoxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-02-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

- 40 -

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160°C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (R_f 0.67 for desired product and R_f 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

- 41 -

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyl-
diphenylsilyl-5-methyluridine**

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyl-5-methyluridine as white foam (21.81g, 86%).

5'-O-tert-butyl-5-methyluridine-2'-O-([2-phthalimidoxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 hr the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1g) was added and the mixture for 1 hr. Solvent was removed under vacuum; residue chromatographed to get 5'-O-

- 42 -

tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95, 78%).

5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert
10 atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 hr, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate
15 (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to
20 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and
25 extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-
30 methyluridine as a white foam (14.6g, 80%).

- 43 -

2'-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then
5 added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and
10 eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight at
15 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at
20 room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂ (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

25 **5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To
30 the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P₂O₅ under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous

- 44 -

acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO₃ (40mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

Example 2

Oligonucleotide Synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as per the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 seconds and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 hr), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution.

Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

- 45 -

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

20 Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

- 46 -

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

- 47 -

**[2'-O-Me] -- [2'-deoxy] -- [2'-O-Me] Chimeric
Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 Ammonia/Ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hours at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hours at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

**[2'-O-(2-Methoxyethyl)] -- [2'-deoxy] -- [2'-O-(Methoxyethyl)] Chimeric Phosphorothioate
Oligonucleotides**

[2'-O-(2-methoxyethyl)] -- [2'-deoxy] -- [2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

- 48 -

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy
Phosphorothioate]--[2'-O-(2-Methoxyethyl)
Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)--[2'-deoxy phos-
5 phorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric
oligonucleotides are prepared as per the above procedure for
the 2'-O-methyl chimeric oligonucleotide with the substitution
of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites,
oxidization with iodine to generate the phosphodiester
10 internucleotide linkages within the wing portions of the
chimeric structures and sulfurization utilizing 3,4,5-trimethyl-
benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate
the phosphorothioate internucleotide linkages for the center
gap.

15 Other chimeric oligonucleotides, chimeric oligonucleo-
sides and mixed chimeric oligonucleotides/oligonucleosides are
synthesized according to U.S. Patent 5,623,065, herein
incorporated by reference.

Example 6

20 Oligonucleotide Isolation

After cleavage from the controlled pore glass column
(Applied Biosystems) and deblocking in concentrated ammonium
hydroxide at 55°C for 18 hours, the oligonucleotides or
oligonucleosides were purified by precipitation twice out of
25 0.5 M NaCl with 2.5 volumes ethanol. Synthesized
oligonucleotides were analyzed by polyacrylamide gel
electrophoresis on denaturing gels and judged to be at least
85% full length material. The relative amounts of
phosphorothioate and phosphodiester linkages obtained in
30 synthesis were periodically checked by ³¹P nuclear magnetic
resonance spectroscopy, and for some studies oligonucleotides
were purified by HPLC, as described by Chiang et al., *J. Biol.*
Chem., 1991, 266, 18162-18171. Results obtained with HPLC-

- 49 -

purified material were similar to those obtained with non-HPLC purified material.

Example 7

Analysis of Oligonucleotide Inhibition of Novel Anti-apoptotic

5 bcl-2-related Protein Expression

Antisense modulation of novel anti-apoptotic bcl-2-related protein expression can be assayed in a variety of ways known in the art. For example, mRNA levels can be quantitated by Northern blot analysis, RNase protection assay (RPA),
10 competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 1, John Wiley & Sons, Inc., 1993, pp. 4.1.1-
15 4.2.9 and 4.5.1-4.5.3. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 1, John Wiley & Sons, Inc., 1996, pp. 4.2.1-4.2.9. Real-time quantitative (PCR) can be conveniently accomplished using the commercially
20 available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Other methods of PCR are also known in the art. Probes and primers are designed to hybridize to the target nucleic acid sequence, using published sequence
25 information (for example, Genbank accession no. U29680 for human A1 and Genbank accession no. L08246 for human mcl-1.

Novel anti-apoptotic bcl-2-related protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis
30 (immunoblotting), ELISA, flow cytometry or fluorescence-activated cell sorting (FACS). Antibodies directed to bcl-2-related proteins can be identified and obtained from a variety of sources, such as PharMingen Inc., San Diego CA, or can be prepared via conventional antibody generation methods.

- 50 -

Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1997, pp. 11.12.1-11.12.9. Preparation of monoclonal antibodies is taught in, 5 for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1997, pp. 11.4.1-11.11.5.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, et al., *Current* 10 *Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1998, pp. 10.16.1-10.16.11. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1997, pp. 10.8.1-15 10.8.21. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1991, pp. 11.2.1-11.2.22.

Example 8

20 RNase Protection Assay for Analysis of mRNA Levels

The ribonuclease (RNase) protection assay is a sensitive and specific method for quantitating expression levels (Zinn, et al., *Cell*, 1983, 34:865-79). The method is based on the hybridization of a target RNA to an *in vitro* transcribed 25 ³²P-labeled anti-sense RNA probe from a DNA template. RNase treatment follows, resulting in degradation of single-stranded RNA and excess probe. The probe and target RNA are resolved by denaturing polyacrylamide gel electrophoresis with the "protected" probe visualized using autoradiography or beta 30 imaging equipment. Template sets can be purchased (PharMingen Inc., San Diego, CA) which contain a series of biologically relevant templates, each of distinct length and each representing a sequence in a distinct mRNA species. Each

- 51 -

template set is capable of detecting up to 11 unique gene messages in a single reaction mix in addition to one or more housekeeping genes, L32 and GAPDH, which serve as internal controls. These template sets allow for multiple determinations to be made from a single sample. Multi-probe RPA can be performed on total RNA preparations derived by standard methods, without further purification of poly-A⁺ RNA.

Oligonucleotides were evaluated for their respective effects on mcl-1 mRNA levels along with total bcl-x mRNA levels, using the RIBOQUANT[™] RNase protection kit (Pharmingen, San Diego, CA). All assays were performed according to manufacturer's protocols. Briefly, multi-probe DNA template sets were used to generate antisense RNA transcripts radiolabeled with dUTP-³²P. The template set used for apoptosis genes was the human hAPO-2 set. These radiolabeled probes were hybridized overnight with typically 10 µg of total cellular RNA. The reaction mixture was then digested with single-strand RNases to generate the protected fragments which were electrophoresed through a 5% acrylamide/urea gel. Protected bands were visualized and quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

Example 9

Antisense Inhibition of Human A1 Expression- Phosphorothioate Oligodeoxynucleotides

In accordance with the present invention, a series of oligonucleotides were designed to target human A1 RNA, using published sequences (Karsan et al., 1996, Blood 87, 3089-3096; Genbank Accession no. U29680, incorporated herein as SEQ ID NO: 1). The oligonucleotides are shown in Table 1.

Table 1
Antisense oligonucleotides targeted to human A1

"Nucl. pos." indicates the position of the first nucleotide on the target sequence (Genbank accession no. U29680; SEQ ID NO: 1) to which the oligonucleotide hybridizes. "PS" = 5 phosphorothioate linkage. "5meC" = 5- methylcytosine. "Deoxy" = 2'-H.

ISIS #	Sequence	Nucl. pos.	Target region	Chemistry	SEQ ID NO:	Activity (% of control)	% Inhib
17483	TGTGCTGAGAAIGCTCACTC	1	5' UTR	PS; deoxy; C = 5meC	2	91	09
17484	TTGAAGCTGTTGAGGCAATG	19	5' UTR	PS; deoxy; C = 5meC	3	55	45
17485	AAGTCTTGAGCTGGCTCACC	39	5' UTR	PS; deoxy; C = 5meC	4	51	49
17486	CTGTCATCTTCTGCCCTGGTG	66	START CODON	PS; deoxy; C = 5meC	5	49	51
17487	CTGTAAATATATCCAAATTC	91	CODING	PS; deoxy; C = 5meC	6	103	--
17488	GCAGATAGTCTTGAGCCAGC	111	CODING	PS; deoxy; C = 5meC	7	52	48
17489	TGGACTGAGAACGCAACATT	193	CODING	PS; deoxy; C = 5meC	8	40	60
17490	AATAGTGTCTTGGCAGTGTCT	271	CODING	PS; deoxy; C = 5meC	9	44	56
17491	TGATGCCGTCTTCAAACTCC	309	CODING	PS; deoxy; C = 5meC	10	45	55
17492	TGCTGTGCTAGAAAGTTTCTT	379	CODING	PS; deoxy; C = 5meC	11	48	52
17493	TCACAGATCTTTCCTGTAAC	556	CODING	PS; deoxy; C = 5meC	12	44	56
17494	TGGAGTGTCTTTCCTGGTCA	604	STOP CODON	PS; deoxy; C = 5meC	13	22	78
17495	ATCGTTTCCATATCAGTCAG	648	3' UTR	PS; deoxy; C = 5meC	14	24	76

- 53 -

17496	CAAAATTTCATAACTCTGG	724	3'UTR	PS; deoxy; C = 5meC	15	36	64
17497	CATACAATTTCATTACATA	750	3'UTR	PS; deoxy; C = 5meC	16	69	31

- 54 -

Oligonucleotides were tested by Northern blot analysis in human umbilical vein endothelial cells (HUVEC) at a concentration of 100 nM. HUVECs were grown to 80% confluency and washed three times with pre-warmed (37°C) Opto-MEM™ (Life Technologies, Inc., Gaithersburg, MD). Oligonucleotides were premixed with 10 µg/ml Lipofectin™ reagent (Life Technologies, Inc., Gaithersburg, MD) in Opti-MEM and applied to washed cells. Cells were incubated with oligonucleotide for 4 hr at 37°C after which the medium was removed and replaced with fresh medium. Total cellular RNA was isolated using an RNeasy™ kit (Qiagen Inc., Valencia, CA). Isolated RNA was separated on a 1% agarose/formaldehyde gel, transferred to a Hybond N+ nylon membrane (Amersham, Arlington Heights, IL) overnight, and UV-crosslinked in a Stratalinker 2400 (Stratagene, La Jolla, CA). Blots were hybridized for several hours with a single-stranded PCR ³²P-labeled probe generated with a primer having the sequence AGAAGTATGTGTTGGCAATCGT (SEQ ID NO: 17) according to published methods. Bednarczuk, T.A. et al., *BioTechniques*, 1991, 10, 478. PCR was used to amplify nucleotides 22 to 684 of the A1 sequence. Northern blots were stripped and reprobed with random-primed ³²P-labeled human G3PDH cDNA to confirm equivalent loading of RNA samples.

The results are shown in Table 1. As can be seen in the table, phosphorothioate oligodeoxynucleotides having SEQ ID NO: 4, 5, 7, 8, 9, 10, 11, 12, 13, 14 and 15 inhibited A1 mRNA expression by approximately 50% or more in this experiment. Of these, ISIS 17494 (SEQ ID NO: 13, targeting the stop codon) and ISIS 17495, SEQ ID NO: 14, targeting the 3' UTR just downstream of the stop codon, gave over 75% inhibition of A1 expression.

- 55 -

Example 10**Antisense Inhibition of A1 Expression- Mixed Backbone 2'-MOE
Gapmer Oligonucleotides**

A second series of oligonucleotides targeted to human
5 A1 was synthesized. The oligonucleotides are shown in Table
2. Target sites are indicated by nucleotide numbers, as given
in the sequence source reference to which the oligonucleotide
binds.

All compounds in Table 2 are chimeric oligonucleotides
10 ("gapmers") 20 nucleotides in length, composed of a central
"gap" region consisting of ten 2'-deoxynucleotides, which is
flanked on both sides (5' and 3' directions) by five-
nucleotide "wings". The wings are composed of 2'-O-
methoxyethyl (2'-MOE) nucleotides. The internucleoside
15 (backbone) linkages are phosphorothioate (P=S) in the deoxy
gap and phosphodiester (P=O) in the wings. Cytidine residues
throughout the molecule are 5-methylcytidines.
Oligonucleotides were tested by Northern blot analysis as
described in the previous example. Results are shown in Table
20 2.

Table 2
Gapped chimeric oligonucleotides targeted to A1

"Nucl. pos." indicates the position of the first nucleotide on the target sequence (Genbank accession no. U29680; SEQ ID NO: 1) to which the oligonucleotide hybridizes. "N.D." indicates no data available. "ps" = phosphorothioate linkage; "PO" = phosphodiester linkage. "Deoxy" = 2'H; "2'MOE" = 2'-O-methoxyethyl. "5meC" = 5- methylcytosine.

ISIS #	Sequence	Nucl. pos.	Target region	Chemistry	SEQ ID NO:	Activity (% of control)	%Inhib
17498	TGTGCTGAGAATGCTCACTC	1	5' UTR	2'MOE/deoxy; PO/PS C = 5meC	2	64	36
17499	TTGAAGCTGTTGAGGCAATG	19	5' UTR	2'MOE/deoxy; PO/PS C = 5meC	3	25	75
17500	AAGTCTTGAGCTGGCTCACC	39	5' UTR	2'MOE/deoxy; PO/PS C = 5meC	4	44	56
17501	CTGTCACTCTTGCCTGGTG	66	START CODON	2'MOE/deoxy; PO/PS C = 5meC	5	13	87
17502	CTGTAAATATATCCAAATTC	91	CODING	2'MOE/deoxy; PO/PS C = 5meC	6	N.D.	
17503	GCAGATAGTCTTGAGCCAGC	111	CODING	2'MOE/deoxy; PO/PS C = 5meC	7	24	76

17504	TGGACTGAGAACGCAACATT	193	CODING	2'MOE/deoxy; PO/PS C = 5meC	8	16	84
17505	AATAGTGTCTCTGGCAGTGTC	271	CODING	2'MOE/deoxy; PO/PS C = 5meC	9	11	89
17506	TGATGCCGCTCTTCAAACTCC	309	CODING	2'MOE/deoxy; PO/PS C = 5meC	10	15	85
17507	TGCTGTCTGTAGAAAGTTTCTT	379	CODING	2'MOE/deoxy; PO/PS C = 5meC	11	9.3	90.7
17508	TCACAGATCTTTCCCTGTAAC	556	CODING	2'MOE/deoxy; PO/PS C = 5meC	12	9.5	90.5
17509	TGGAGTGTCCCTTCTGGTCA	604	STOP CODON	2'MOE/deoxy; PO/PS C = 5meC	13	6.7	93.3
17510	ATCGTTTCCATATCAGTCAG	648	3'UTR	2'MOE/deoxy; PO/PS C = 5meC	14	7.6	92.4
17511	CAAAATTTCCATAAATCTGG	724	3'UTR	2'MOE/deoxy; PO/PS C = 5meC	15	15	85
17512	CATACAAATTTATTCATTACA	750	3'UTR	2'MOE/deoxy; PO/PS C = 5meC	16	22	78

- 58 -

As 2'-MOE gapmers, SEQ ID NO: 3, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 gave over 75% reduction in A1 mRNA. Of these, SEQ ID NO: 11 (ISIS 17507), 12 (ISIS 17508), 13 (ISIS 17509) and 14 (ISIS 17510) gave over 90% reduction of A1 expression.

Dose-response experiments using ISIS 17510 (SEQ ID NO: 14, 2' MOE gapmer) gave an IC₅₀ of less than 10 nM for A1 mRNA reduction using this compound.

Northern blot experiments using ISIS 17510 and a probe specific for the bcl-2 family member bcl-X demonstrated that the A1 antisense compound did not affect bcl-x mRNA levels.

Example 11

Antisense Inhibition of A1 Expression- Mixed Backbone 2'-MOE Hemimer Oligonucleotides

A third series of oligonucleotides targeted to human A1 was synthesized. The oligonucleotides are shown in Table 3. Target sites are indicated by nucleotide numbers, as given in the sequence source reference to which the oligonucleotide binds.

All compounds in Table 3 are chimeric "hemimer" oligonucleotides 20 nucleotides in length, composed of ten contiguous 2'-deoxynucleotides, joined to ten contiguous 2'-O-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) in the deoxy region and phosphodiester (P=O) in the 2'-MOE region. Cytidine residues throughout the molecule are 5-methylcytidines.

Oligonucleotides were tested by Northern blot analysis as described in previous examples. Results are shown in Table 3.

Table 3
"Hemimer" chimeric oligonucleotides targeted to A1

"Nucl. pos." indicates the position of the first nucleotide on the target sequence (Genbank accession no. U29680; SEQ ID NO: 1) to which the oligonucleotide hybridizes. "PS" = phosphorothioate linkage; "PO" = phosphodiester linkage. "Deoxy" = 2'H; "2'MOE" = 2'-O-methoxyethyl. "5meC" = 5-methylcytosine.

ISIS #	Sequence	Nucl. pos.	Target region	Chemistry	SEQ ID NO:	Activity (% of control)	% Inhib
17513	TGTGCTGAGAAATGCTCACTC	1	5' UTR	Deoxy/2'MOE; PS/PO C = 5meC	2	73	27
17514	TTGAAGCTGTTGAGGCAATG	19	5' UTR	Deoxy/2'MOE; PS/PO C = 5meC	3	40	60
17515	AAGTCTTGAGCTGGCTCACC	39	5' UTR	Deoxy/2'MOE; PS/PO C = 5meC	4	30	70
17516	CTGTCACTCTTCTGCCTGGTG	66	START CODON	Deoxy/2'MOE; PS/PO C = 5meC	5	32	68
17517	CTGTAAATATATCCAAATTC	91	CODING	Deoxy/2'MOE; PS/PO C = 5meC	6	26	74
17518	GCAGATAGTCCCTGAGCCAGC	111	CODING	Deoxy/2'MOE; PS/PO C = 5meC	7	32	68
17519	TGGACTGAGAACGCAACATT	193	CODING	Deoxy/2'MOE; PS/PO C = 5meC	8	32	68

17520	AATAGTGTTCGGCAGTGTCTC	271	CODING	Deoxy/2'MOE; PS/PO C = 5meC	9	37	63
17521	TGATGCCGCTCTTCAAACTCC	309	CODING	Deoxy/2'MOE; PS/PO C = 5meC	10	29	71
17522	TGCTGTCGTAGAAAGTTTCTT	379	CODING	Deoxy/2'MOE; PS/PO C = 5meC	11	23	77
17523	TCACAGATCTTTCCCTGTAAC	556	CODING	Deoxy/2'MOE; PS/PO C = 5meC	12	16	84
17524	TGGAGTGTCCCTTCTGGTCA	604	STOP CODON	Deoxy/2'MOE; PS/PO C = 5meC	13	8.5	91.5
17525	ATCGTTTCCATATCAGTCAG	648	3'UTR	Deoxy/2'MOE; PS/PO C = 5meC	14	13	87
17526	CAAAATTCCATAACTCTGG	724	3'UTR	Deoxy/2'MOE; PS/PO C = 5meC	15	64	36
17527	CATACAATTATTCATTACA	750	3'UTR	Deoxy/2'MOE; PS/PO C = 5meC	16	47	53

- 61 -

As 2' MOE hemimers, SEQ ID NO: 11 (ISIS 17522), 12 (ISIS 17523), 13 (ISIS 17524) and 14 (ISIS 17525) gave at least 75% inhibition of A1 mRNA levels. Of these, ISIS 17524 (SEQ ID NO: 13) gave over 90% inhibition.

5 Example 12

Antisense Inhibition of Human mcl-1 Expression- Phosphorothioate 2'-moe Gapmer Oligonucleotides

In accordance with the present invention, a series of oligonucleotides were designed to target human mcl-1 RNA, using published sequences (Kozopas et al., Proc. Natl. Acad. Sci. USA., 1993, 90, 3516-3520, Genbank Accession No. L08246, incorporated herein as SEQ ID NO: 18). The oligonucleotides are shown in Table 4. All compounds in Table 4 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-O-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout. Cytidine residues throughout the molecule are 5-methylcytidines.

Oligonucleotides were tested by Northern blot analysis approximately as described in previous examples, using the human melanoma cell line C8161 (a gift of Dr. Dan Welch, Hershey Medical Center, Hershey, PA). Oligonucleotide (100 nM) and Lipofectin™ (10 µg/ml) were mixed and incubated for 30 minutes at room temperature. Cells were washed twice with Opti-MEM™, oligonucleotide mixture was added and cells were incubated at 37° for 4 hours. Oligonucleotide was replaced with fresh medium (RPMI with 10% FCS). 24 hours later, RNA was isolated using the Rneasy™ kit (Qiagen, Valencia, CA). RNA was electrophoresed, transferred to nitrocellulose and probed with a random-primed mcl-1 EST probe (ATCC 1064916

- 62 -

I.M.A.G.E. Clone ID: 796506), obtained from the American Type Culture Collection (Manassas, VA) and labeled with the Stripeasy™ kit (Ambion, Austin, TX).

Results are shown in Table 4.

Table 4
Antisense oligonucleotides targeted to human mcl-1
 "Nucl. pos." indicates the position of the first nucleotide on the target sequence (Genbank accession no. L08246; SEQ ID NO:18) to which the oligonucleotide hybridizes. "N.D." indicates no data available. "ps" = phosphorothioate linkage; "PO" = phosphodiester linkage. "Deoxy" = 2'H; "2'MOE" = 2'-O-methoxyethyl. "5meC" = 5- methylcytosine.

ISIS #	Sequence	Nucl. pos.	Target region	Chemistry	SEQ ID NO.	Activity (% of control)	% Inhib
20404	GCCAAACATTGCCAGTCGCC	50		PS; 2'MOE/deoxy; C = 5 meC	19	83.2	16.8
20405	AGCCAAAAGTCGCCCTCCCG	152		PS; 2'MOE/deoxy; C = 5 meC	20	72.8	27.2
20406	CTCGTACCCGTCAGTCCT	431		PS; 2'MOE/deoxy; C = 5 meC	21	63.8	36.2
20407	TGTTATTACCAGATTCCCCG	501		PS; 2'MOE/deoxy; C = 5 meC	22	44.1	55.9
20408	TTGGCTTTGTGTCTTGGCG	636		PS; 2'MOE/deoxy; C = 5 meC	23	38.4	61.6
20409	GAGAGTCACAATCCTGCCCC	842		PS; 2'MOE/deoxy; C = 5 meC	24	68.6	31.4
20410	AAAGCCAGCAGCACATTCCT	1045		PS; 2'MOE/deoxy; C = 5 meC	25	66.6	33.4
20411	CCTCTTGCCACTTGCTTTTC	1230		PS; 2'MOE/deoxy; C = 5 meC	26	77.7	22.3

- 64 -

20412	CACAGGTCACCTGGCATTCTT	1519		PS; 2'MOE/deoxy; C = 5 meC	27	97.4	2.6
20413	AAGAATCATGGAACCAAGCC	1676		PS; 2'MOE/deoxy; C = 5 meC	28	84.1	15.9
20414	CTCTCAATCCCAGGTTTCA	2091		PS; 2'MOE/deoxy; C = 5 meC	29	65.4	34.6
20415	GGTCAATGGAAGGAAGTCA	2231		PS; 2'MOE/deoxy; C = 5 meC	30	71.9	28.1
20416	CAATGTCTCTCCATCCACC	2366		PS; 2'MOE/deoxy; C = 5 meC	31	37.5	62.5
20417	AAATCCAAAGATGCCAATGC	2564		PS; 2'MOE/deoxy; C = 5 meC	32	159.5	--
20418	CAGTGCCAAAATCTAAAAGG	2722		PS; 2'MOE/deoxy; C = 5 meC	33	87.5	12.5
20419	CTTCTCCACCTCTCAATG	2866		PS; 2'MOE/deoxy; C = 5 meC	34	N.D.	
20420	GGCAGTTCTTCCCCATTACA	3207		PS; 2'MOE/deoxy; C = 5 meC	35	43.8	56.2
20421	ATTGGCAGACAGGCTTTTA	3391		PS; 2'MOE/deoxy; C = 5 meC	36	50.6	49.4
20422	TAGACCACCTGCCTCCTCCT	3591		PS; 2'MOE/deoxy; C = 5 meC	37	62.5	37.5
20423	GTCCTAACCCCTTCCTGGCAC	3821		PS; 2'MOE/deoxy; C = 5 meC	38	68.8	31.2

- 65 -

SEQ ID NO: 22 (ISIS 20407), 23 (ISIS 20408), 31 (ISIS 20416), 35 (ISIS 20420), and 36 (ISIS 20421) inhibited mcl-1 mRNA levels by approximately 50% or more. Of these, ISIS 20408 and 20416 showed greatest reduction of mcl-1 expression.

5 A dose-response experiment was done using ISIS 20407, 20408 and 20416. RNase protection assay was used to detect mcl-1 mRNA levels, using the hApo2 probe set (Pharmingen, San Diego, CA). ISIS 20407 demonstrated an IC₅₀ of approximately 100 nM. ISIS 20408 and 20416 demonstrated IC₅₀s of
10 approximately 25 nM.

Example 13

Scid-human Leukemia Xenograft Model and Measurement of Apoptosis in Xenografts

10⁷ SEM-K2 cells in exponential phase of growth are
15 injected subcutaneously into 8 SCID-NOD mice as a bolus (suspended in sterile saline). Engraftment and tumor formation occurs over a 2-3 week period. Micro Alzet pumps (Alza, Newark, DE) capable of delivering a continuous subcutaneous infusion over 14 days are used to deliver a dose
20 of 100 µg per day (equivalent to 5 mg/kg) of antisense oligonucleotide into three animals. The remaining two animals received vehicle (sterile saline) only.

The expression of target protein measured in SEM-K2 cells from SCID-hu xenografts is measured using quantitative flow
25 cytometry.

Xenografts are removed after sacrifice and mechanically dispersed into large volumes of medium. Leukocytes are purified by density gradient centrifugation and washed with medium before resuspending in 1 ml volumes at 1-5 x 10⁶
30 cells/ml. Cells are incubated at 37° C in 95% humidified air/5% CO₂ for 2 hours prior to induction of apoptosis with 20 µg/ml VP16 (Etoposide) over 24 hours. Apoptosis is assessed nonspecifically using quantification of light scatter changes;

- 66 -

reduction in side scatter (due to chromatin condensation) and reduction in forward scatter (due to cell shrinkage) are early changes associated with apoptosis. Bimodal population distributions consisting of apoptotic and non-apoptotic cells can be measured respectively allowing estimation of an apoptotic index for treated and negative control. Fold increase in apoptosis is calculated from their ratio. More specific determination of apoptosis is achieved using the Apo-Alert Caspase-3 Colorimetric Assay Kit (Clontech, Palo Alto, CA). This is a DEVD-specific caspase assay, a quantitative assay for the activity of caspase-3, a member of the caspase family thought to mediate apoptosis in most mammalian cell types. This assay utilizes a synthetic tetrapeptide, Asp-Glu-Val-Asp (DEVD) (SEQ ID NO: 39), labeled with either a fluorescent molecule, 7-amino-4-trifluoromethyl coumarin (AFC), or a colorimetric molecule, p-nitroanilide (pNA) as substrates. DEVD-dependent protease activity is assessed by detection of the free AFC or pNA cleaved from the substrates. Cell lysates are incubated with DEVD conjugated to paranitroanilide, a colorimetric substrate cleaved by CPP32 (caspase-3) and detectable using colorimetric spectrophotometry at 405 nm. The fold increase in OD_{405nm} is used to determine the net VP16-induced apoptosis.

Example 14

Western blot analysis of mcl-1 protein levels in C8161 cells

Western blot analysis (immunoblot analysis) was carried out using standard methods. C8161 cells were transfected in 5 mL volumes at approximately 8×10^5 cells/10 cm plate. 200 nM of ISIS 20408 (SEQ ID NO: 23) or 8-basepair mismatch control ISIS 105232; TGGGTCTGCTTCTCTGTCG; SEQ ID NO: 40) was added to cells with cationic lipid. Cells were analyzed at fixed intervals after treatment.

For Western blot analysis, cells were washed once in phosphate-buffered saline and pelleted by centrifugation at

- 67 -

1200 rpm for 5 minutes, and resuspended in cell lysis buffer (5M NaCl, 0.1 M HEPES, 500 mM sucrose, 0.5M EDTA, 100 mM spermine, 1 mg/ml aprotinin, 10% Triton X-100) for 15 minutes on ice. Total protein was quantified spectrophotometrically (BioRad) and 100 μ g lysate was loaded onto 15% polyacrylamide gels and run at 200V for 45 minutes. Following protein transfer to nitrocellulose membrane, blots were immunostained with primary mcl-1 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz CA) followed by horseradish peroxidase-conjugated goat anti-mouse secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz CA). Protein was qualitatively visualized by ECL (Amersham, Piscataway NJ) and exposure on photographic film.

ISIS 20408 was tested for the ability to reduce mcl-1 protein levels in C8161 cells, and was found to reduce mcl-1 protein levels by 90% after 4 hours, at an oligonucleotide dose of 200nM.

Example 15

Ultraviolet Irradiation of C8161 cells

C8161 cells were irradiated with UV-B light when they were approximately 70-80% confluent or 24 hours after treatment with oligonucleotide. Immediately before UV-B treatment, cells were washed twice with PBS and then exposed to UV-B light in a Stratalinker UV Crosslinker 1800 model (Stratagene, La Jolla CA) containing 5 15-watt 312 nm bulbs. The cells were exposed to 0 mJ/m², 5 mJ/m² or 10 mJ/m² of UV-B radiation. The dose of UV-B radiation was calibrated using a UVX radiometer (UVP). Following UV irradiation, the cells were incubated in the standard medium for an additional 24 hours. Control plates for UV-B treatment were simply washed 3 times in PBS and incubated in the standard medium for an additional 24 hours. Cells were examined for apoptosis by staining the ethanol-fixed cell nuclei with propidium iodide and examining the DNA content by flow cytometry. Apoptotic cells were

- 68 -

identified by their sub-diploid DNA content. Cells were washed twice with cold PBS and resuspended in 1 ml of 70% ethanol. After 1 hour incubation at room temperature, cells were washed in PBS and resuspended in 1 ml propidium iodide staining
5 solution (50 μ g/ml propidium iodide, 0.5 U/ml RNase A, 2000 U/ml RNase T1. After 30 minutes at room temperature, cell cycle analysis was performed by flow cytometry using a Becton Dickinson Calibur FACS analyzer. The fluorescence of individual nuclei of 10,000 cells was measured using a FACScan
10 flow cytometer. Results were expressed as percentage apoptotic cells.

Example 16**Antisense sensitization of C8161 cells to UV-induced cell death**

15 C8161 cells were treated with 200 nM ISIS 20408 or the 8-basepair mismatch control (ISIS 105232; SEQ ID NO: 40) and exposed to ultraviolet (UV) radiation as described in the previous example. The percent apoptotic cells was quantitated by propidium iodide staining according to standard methods.
20 Results are shown in Table 5.

Table 5**Combination of ISIS 20408 and UV irradiation**

Compound	UV mJ/M ²	% Apoptotic cells (approx)	SEQ ID NO:
No oligo	0	0.2	--
	5	1.0	--
	10	5.2	--
25 ISIS 20408	0	2	23
	5	4.7	" "
	10	11.5	" "
ISIS 105232	0	0.5	40
	5	1.5	" "

- 69 -

	10	6.3	" "
--	----	-----	-----

Thus the antisense treatment resulted in increased apoptosis; i.e., sensitization to UV-induced apoptosis.

Example 17

Cisplatinium Treatment of C8161 Cells

- 5 Cisplatinium is an alkylating agent that causes DNA damage and can induce apoptosis. Gill and Windebank, 1998, J. Clin. Invest. 101:2842-2850. C8161 cells were treated with cisplatinium when they were approximately 70-80% confluent or 24 hours after treatment with oligonucleotide. Cis-
- 10 diamminedichloroplatinium II (Cisplatinium, Sigma, St. Louis MO) was dissolved in distilled water at a concentration of 1 mg/ml, and was added to the standard medium at a dose range of 2.5 to 10 μ g/ml and incubated with cells for 24 hours.

15 Example 18

Antisense sensitization of C8161 cells to cisplatinium-induced cell death

- C8161 cells were treated with 200 nM ISIS 20408 or the 8-basepair mismatch control ISIS 105232 and cisplatinium at
- 20 various doses. The percent apoptotic cells was quantitated by propidium iodide staining according to standard methods as described in previous examples. Results are shown in Table 6.

Table 6

Combination of ISIS 20408 and Cisplatinium

25

Compound	Cisplatinium dose (μ g/ml)	% Apoptotic cells (approx)	SEQ ID NO:
No oligo	0	2	--
	2.5	5	--
	5	11	--
	10	30	--

- 70 -

ISIS 20408	0	11.5	23
	2.5	39	" "
	5	40	" "
	10	80	" "
ISIS 105232	0	4	40
	2.5	11.5	" "
	5	17.5	" "
	10	52	" "

Thus the cells have been sensitized to the apoptotic stimulus
(in this case the cytotoxic chemotherapeutic drug cisplatinum)
5 after antisense treatment resulting in increased apoptosis.

- 71 -

What is claimed is:

1. An antisense compound 8 to 30 nucleotides in length targeted to a nucleic acid molecule encoding a novel anti-apoptotic bcl-2-related protein, wherein said antisense
5 compound modulates the expression of said novel anti-apoptotic bcl-2-related protein.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein the
10 antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The antisense compound of claim 3 wherein the modified internucleoside linkage of the antisense oligonucleotide is a phosphorothioate linkage.
- 15 5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The antisense compound of claim 5 wherein the modified sugar moiety of the antisense oligonucleotide is a
20 2'-O-methoxyethyl sugar moiety.
7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 25 8. The antisense compound of claim 7 wherein the modified nucleobase is a 2'-O-methoxyethyl modified cytosine.

- 72 -

9. The antisense compound of claim 8 wherein the modified nucleobase of the antisense oligonucleotide is a 5-methylcytosine.

10. The antisense compound of claim 1 which is a 5 chimeric oligonucleotide.

11. The antisense compound of claim 1 which is targeted to a nucleic acid encoding human A1.

12. The antisense compound of claim 11 wherein the antisense oligonucleotide comprises SEQ ID NO: 3, 4, 5, 6, 7,
10 8, 9, 10, 11, 12, 13, 14, 15 or 16.

13. The antisense compound of claim 1 which is targeted to a nucleic acid encoding human mcl-1.

14. The antisense compound of claim 13 wherein the antisense oligonucleotide comprises SEQ ID NO: 22, 23, 31, 35,
15 or 36.

15. A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

16. The pharmaceutical composition of claim 15 further
20 comprising a colloidal dispersion system.

17. The pharmaceutical composition of claim 15 further comprising a chemotherapeutic agent for the treatment of cancer.

18. A method of inhibiting the expression of a novel
25 anti-apoptotic bcl-2-related protein in cells or tissues comprising contacting said cells or tissues with the antisense

- 73 -

compound of claim 1 so that expression of said novel anti-apoptotic bcl-2-related protein is inhibited.

19. The method of claim 18 wherein the antisense compound is targeted to a nucleic acid molecule encoding human
5 A1.

20. The method of claim 18 wherein the antisense compound is targeted to a nucleic acid molecule encoding human mcl-1.

21. A method of promoting apoptosis in human cells or
10 tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of said novel anti-apoptotic bcl-2-related protein is inhibited.

22. The method of claim 21 wherein the antisense compound is targeted to a nucleic acid molecule encoding human
15 A1.

23. The method of claim 21 wherein the antisense compound is targeted to a nucleic acid molecule encoding human mcl-1.

24. A method of treating a human having a disease or
20 condition associated with a novel anti-apoptotic bcl-2-related protein comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of said novel anti-apoptotic bcl-2-related protein is inhibited.

25. The method of claim 24 wherein the antisense compound is targeted to a nucleic acid molecule encoding human
A1.

- 74 -

26. The method of claim 24 wherein the antisense compound is targeted to a nucleic acid molecule encoding human mcl-1.

27. A method of treating a human having a disease or
5 condition characterized by a reduction in apoptosis comprising administering to said human a prophylactically or therapeutically effective amount of the antisense compound of claim 1.

28. The method of claim 27 wherein the antisense
10 compound is targeted to a nucleic acid molecule encoding human A1.

29. The method of claim 27 wherein the antisense compound is targeted to a nucleic acid molecule encoding human mcl-1.

30. A method of treating a human having a disease or
15 condition for which promotion of apoptosis is desired comprising administering to said human a prophylactically or therapeutically effective amount of the antisense compound of claim 1.

31. The method of claim 30 wherein the antisense
20 compound is targeted to a nucleic acid molecule encoding human A1.

32. The method of claim 30 wherein the antisense
25 compound is targeted to a nucleic acid molecule encoding human mcl-1.

33. A method of treating cancer in a patient comprising:

- 75 -

(a) administering to the patient a pharmaceutical composition of claim 15; and

(b) administering to the patient a chemotherapeutic agent for the treatment of cancer.

5 34. The pharmaceutical composition of claim 17 wherein the chemotherapeutic agent for the treatment of cancer is cisplatinum.

35. A method of sensitizing human cells or tissues to apoptosis comprising contacting said cells or tissues with the
10 antisense compound of claim 1 so that expression of said novel anti-apoptotic bcl-2-related protein is inhibited.

36. The method of claim 35 wherein said antisense compound is administered in combination with an apoptotic stimulus.

15 37. The method of claim 36 wherein the apoptotic stimulus is radiation or a chemotherapeutic agent.

38. The method of claim 37 wherein the chemotherapeutic agent is cisplatinum.

39. A method of sensitizing human cells or tissues to
20 an apoptotic stimulus comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of said novel anti-apoptotic bcl-2-related protein is inhibited.

40. The method of claim 39 wherein the apoptotic
25 stimulus is radiation or a chemotherapeutic agent.

41. The method of claim 40 wherein the chemotherapeutic agent is cisplatinum.

Docket No.

ISPH-0573

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Antisense Modulation of Novel Anti-Apoptotic BCL-2-Related Proteins

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on December 14, 1999 as United States Application No. or PCT International Application Number PCT/US99/29593 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/226,568

January 7, 1999

Patented

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



26259

PATENT TRADEMARK OFFICE

Herb Boswell, Reg. No. 27,311
 Laurel Spear Bernstein, Reg. No. 37,280
 Robert S. Andrews, Reg. No. 44,508
 April Logan, Reg. No. 33,950
 Neil S. Bartfeld, Reg. No. 39,901
 Kenneth H. Tarbet, Reg. No. 43,181
 of the firm
 ISIS Pharmaceuticals, Inc.
 Carlsbad Research Center
 2292 Faraday Avenue
 Carlsbad, California 92008


Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor Elizabeth J. Ackermann
Sole or first inventor's signature <i>Elizabeth J. Ackermann</i> Date <i>8-17-01</i>
Residence Solana Beach, California
Citizenship US
Post Office Address 519 Santa Victoria
Solana Beach, California 92075

Full name of second inventor, if any C. Frank Bennett
Second inventor's signature Date
Residence Carlsbad, California
Citizenship US
Post Office Address 1347 Cassins Street
Carlsbad, California 92008

Full name of third inventor, if any Nicholas M. Dean	
Third inventor's signature 	Date 8/30/01
Residence Olivenhein, California	
Citizenship UK	
Post Office Address 2110 Whisperwind Lane	
Olivenhein, California 92024	

Full name of fourth inventor, if any Eric G. Marcusson	
Fourth inventor's signature	Date
Residence San Diego, California	
Citizenship US	
Post Office Address 6369 Caminito de Pastel	
San Diego, California 92111	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Docket No.

ISPH-0573

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Antisense Modulation of Novel Anti-Apoptotic BCL-2-Related Proteins

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on December 14, 1999 as United States Application No. or PCT International Application Number PCT/US99/29593 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/226,568

January 7, 1999

Patented

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)


(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



Herb Boswell, Reg. No. 27,311
 Laurel Spear Bernstein, Reg. No. 37,280
 Robert S. Andrews, Reg. No. 44,508
 April Logan, Reg. No. 33,950
 Neil S. Bartfeld, Reg. No. 39,901
 Kenneth H. Tarbet, Reg. No. 43,181
 of the firm
 ISIS Pharmaceuticals, Inc.
 Carlsbad Research Center
 2292 Faraday Avenue
 Carlsbad, California 92008

Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor Elizabeth J. Ackermann	Date
Sole or first inventor's signature	
Residence Solana Beach, California <i>CA</i>	
Citizenship US	
Post Office Address 519 Santa Victoria	
Solana Beach, California 92075	

Full name of second inventor, if any C. Frank Bennett <i>C. Frank Bennett</i>	Date 7/30/01
Second inventor's signature	
Residence Carlsbad, California <i>CA</i>	
Citizenship US	
Post Office Address 1347 Cassins Street	
Carlsbad, California 92008	

30

Full name of third inventor, if any Nicholas M. Dean	
Third inventor's signature	Date
Residence Olivenhein, California <i>CH</i>	
Citizenship UK	
Post Office Address 2110 Whisperwind Lane	
Olivenhein, California 92024	

40

Full name of fourth inventor, if any Eric G. Marcusson	7/30/01
Fourth inventor's signature <i>Eric G. Marcusson</i>	Date
Residence San Diego, California <i>CH</i>	
Citizenship US	
Post Office Address 6369 Caminito de Pastel	
San Diego, California 92111	

1. Inventor's name
 2. Inventor's address
 3. Inventor's citizenship
 4. Inventor's post office address
 5. Inventor's residence
 6. Inventor's signature
 7. Inventor's date
 8. Inventor's residence
 9. Inventor's citizenship
 10. Inventor's post office address
 11. Inventor's signature
 12. Inventor's date
 13. Inventor's residence
 14. Inventor's citizenship
 15. Inventor's post office address
 16. Inventor's signature
 17. Inventor's date
 18. Inventor's residence
 19. Inventor's citizenship
 20. Inventor's post office address
 21. Inventor's signature
 22. Inventor's date
 23. Inventor's residence
 24. Inventor's citizenship
 25. Inventor's post office address
 26. Inventor's signature
 27. Inventor's date
 28. Inventor's residence
 29. Inventor's citizenship
 30. Inventor's post office address
 31. Inventor's signature
 32. Inventor's date
 33. Inventor's residence
 34. Inventor's citizenship
 35. Inventor's post office address
 36. Inventor's signature
 37. Inventor's date
 38. Inventor's residence
 39. Inventor's citizenship
 40. Inventor's post office address
 41. Inventor's signature
 42. Inventor's date
 43. Inventor's residence
 44. Inventor's citizenship
 45. Inventor's post office address
 46. Inventor's signature
 47. Inventor's date
 48. Inventor's residence
 49. Inventor's citizenship
 50. Inventor's post office address
 51. Inventor's signature
 52. Inventor's date
 53. Inventor's residence
 54. Inventor's citizenship
 55. Inventor's post office address
 56. Inventor's signature
 57. Inventor's date
 58. Inventor's residence
 59. Inventor's citizenship
 60. Inventor's post office address
 61. Inventor's signature
 62. Inventor's date
 63. Inventor's residence
 64. Inventor's citizenship
 65. Inventor's post office address
 66. Inventor's signature
 67. Inventor's date
 68. Inventor's residence
 69. Inventor's citizenship
 70. Inventor's post office address
 71. Inventor's signature
 72. Inventor's date
 73. Inventor's residence
 74. Inventor's citizenship
 75. Inventor's post office address
 76. Inventor's signature
 77. Inventor's date
 78. Inventor's residence
 79. Inventor's citizenship
 80. Inventor's post office address
 81. Inventor's signature
 82. Inventor's date
 83. Inventor's residence
 84. Inventor's citizenship
 85. Inventor's post office address
 86. Inventor's signature
 87. Inventor's date
 88. Inventor's residence
 89. Inventor's citizenship
 90. Inventor's post office address
 91. Inventor's signature
 92. Inventor's date
 93. Inventor's residence
 94. Inventor's citizenship
 95. Inventor's post office address
 96. Inventor's signature
 97. Inventor's date
 98. Inventor's residence
 99. Inventor's citizenship
 100. Inventor's post office address

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

SEQUENCE LISTING

<110> Ackermann, Elizabeth J.
 Bennett, C. Frank
 Dean, Nicholas M.
 Marcusson, Eric G.
 Isis Pharmaceuticals, Inc.

<120> Antisense Modulation of Novel Anti-apoptotic bcl-2-Related
 Proteins

<130> ISPH-0432

<140>

<141>

<150> 09/226,568

<151> 1999-01-07

<160> 40

<170> PatentIn Ver. 2.0

<210> 1

<211> 780

<212> DNA

<213> Homo sapiens

<400> 1

```

gagtgcagcat tctcagcaca ttgcctcaac agcttcaagg tgagccagct caagactttg 60
ctctccacca ggcagaagat gacagactgt gaatttggat atatttacag gctggctcag 120
gactatctgc agtgcgtcct acagatacca caacctggat cagggtccaag caaacgtcc 180
agagtgttac aaaatgttgc gttctcagtc caaaaagaag tggaaaagaa tctgaagtca 240
tgcttggaaca atgttaatgt tgtgtccgta gacactgcca gaacactatt caaccaagt 300
atggaaaagg agtttgaaga cggcatcatt aactggggaa gaattgtaac catatttgca 360
tttgaaggta ttctcatcaa gaaacttcta cgacagcaaa ttgccccgga tgtggatacc 420
tataaggaga ttcatattt tgttgccgag ttcataatga ataacacagg agaatggata 480
aggcaaaacg gaggtggga aaatggcttt gtaaagaagt ttgaacctaa atctggctgg 540
atgacttttc tagaagttac aggaaagatc tgtgaaatgc tatctctcct gaagcaatac 600
tggtgaccag aaaggacact ccatattgtg aaaccggcct aatttttctg actgatatgg 660
aaacgattgc caacacatac ttctactttt aaataaacia ctttgatgat gtaacttgac 720
cttcagagat tatggaaatt ttgtcccat gtaatgaata aattgtatgt atttttctct 780

```

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 2

tgtgctgaga atgctcactc

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 3
ttgaagctgt tgaggcaatg 20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 4
aagtcttgag ctggctcacc 20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 5
ctgtcatctt ctgcctggtg 20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 6
ctgtaaatat atccaaattc 20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 7
gcagatagtc ctgagccagc 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 8
tggactgaga acgcaacatt 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 9
aatagtgttc tggcagtgtc 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 10
tgatgccgtc ttcaaactcc 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 11
tgctgtcgta gaagtttctt 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 12
tcacagatct ttcctgtaac 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 13
tggagtgtcc tttctggtca 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 14
atcgtttcca tatcagtcag 20

<210> 15

<211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: antisense sequence

<400> 15
 caaaatttcc ataactctgg 20

<210> 16
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: antisense sequence

<400> 16
 catacaattt attcattaca 20

<210> 17
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: antisense sequence

<400> 17
 agaagtatgt gttggcaatc gt 22

<210> 18
 <211> 3934
 <212> DNA
 <213> Homo sapiens

<220>
 <223> Description of Artificial Sequence: antisense sequence

<400> 18
 tccagtaagg agtcgggggtc ttccccagtt ttctcagcca ggccggcgccg gcgactggca 60
 atgtttggcc tcaaaagaaa cgcggtaatc ggactcaacc tctactgtgg gggggccggc 120
 ttggggggccg gcagcggcgg cgccaccgcg ccgggagggc gacttttggc tacggagaag 180
 gaggcctcgg cccggcgaga gataggggga ggggagggcg gcgcgggtgat tggcggaagc 240
 gcgggcgcaa gcccccgtc caccctcacg ccagactccc ggaggggtcgc gcggccgccc 300
 cccattggcg ccgaggtccc cgacgtcacc gcgacccccg cgaggctgct tttcttcgcg 360
 cccaccgccc gcgcggcgcc gcttgaggag atggaagccc cggccgctga cgccatcatg 420
 tcgcccgaag aggagctgga cgggtacgag ccggagcctc tcgggaagcg gccggctgtc 480
 ctgccgctgc tggagttggg cggggaatct ggtaataaca ccagtacgga cgggtcacta 540
 ccctcgacgc cgccgccagc agaggaggag gaggacgagt tgtaccggca gtcgctggag 600
 attatctctc ggtaccttcg ggagcaggcc accggcgcca aggacacaaa gccaatgggc 660
 aggtctgggg ccaccagcag gaaggcgtcg gagaccttac gacgggttg ggatggcgtg 720
 cagcgcaacc acgagacggg cttccaaggc atgcttcgga aactggacat caaaaacgaa 780
 gacgatgtga aatcgttgtc tcgagtgatg atccatgttt tcagcgacgg cgtaacaaac 840
 tggggcagga ttgtgactct catttctttt ggtgcctttg tggctaaaca cttgaagacc 900
 ataaaccaag aaagctgcat cgaaccatta gcagaaagta tcacagacgt tctcgtaagg 960
 acaaaacggg actggctagt taaacaaaga ggctgggatg ggtttgtgga gttcttccat 1020
 gtagaggacc tagaagggtg catcaggaat gtgctgctgg cttttgcagg tggtgctgga 1080
 gtaggagctg gtttggcata tctaataaga tagccttact gtaagtgcaa tagttgactt 1140
 ttaaccaacc accaccacca caaaaccag tttatgcagt tggactccaa gctgtaactt 1200
 cctagagttg caccctagca acctagccag aaaagcaagt ggcaagagga ttatggctaa 1260
 caagaataaa tacatgggaa gagtgtctcc cattgattga agagtcaactg tctgaaagaa 1320

```

gcaaagttca gtttcagcaa caaacaaact ttgtttggga agctatggag gaggactttt 1380
agatttagtg aagatggttag ggtggaaaga cttaatttcc ttgttgagaa caggaaagtg 1440
gccagtagcc aggcagtgca tagaattgat taccgcgcga attcattaat ttactgtagt 1500
agtggttaaga gaagcactaa gaatgccagt gacctgtgta aaagttacaa gtaatagaac 1560
tatgactgta agcctcagta ctgtacaagg gaagcttttc ctctctctaa ttagctttcc 1620
cagtatactt cttagaaagt ccaagtgttc aggactttta tacctgttat actttggctt 1680
ggttccatga ttcttacttt attagcctag tttatcacca ataatacttg acggaaggct 1740
cagtaattag ttatgaatat ggatatcttc aattcttaag acagcttgta aatgtatttg 1800
taaaaattgt atatattttt acagaaaagtc ttttccttg aaacgaagga agtatcgaat 1860
ttacattagt ttttttcata cccttttgaa ctttgcaact tccgtaatta ggaacctgtt 1920
tcttacagct tttctatgct aaactttgtt ctgttcagtt ctagagtgtg tacagaacga 1980
attgatgtgt aactgtatgc agactggttg tagtggaaca aatctgataa ctatgcaggt 2040
ttaaattttc ttatctgatt ttggtaaagta ttcccttagat aggtttttct tgaaaacctg 2100
ggattgagag gttgatgaat ggaaattctt tcacttcatt atatgcaagt tttcaataat 2160
taggtctaag tggagtttta aggttactga tgacttacaa ataatgggtc ctgattgggc 2220
aatactcatt tgagttcctt ccatttgacc taatttaact ggtgaaattt aaagtgaatt 2280
catgggctca tctttaagc ttttactaaa agattttcag ctgaatggaa ctcatagct 2340
gtgtgcatat aaaaagatca catcaggtgg atggagagac atttgatccc ttgtttgctt 2400
aataaattat aaaaatgatg cttggaaaag caggctagtc taacctaggt gctattatta 2460
ggcttgcttg ttacacacac aggtctaagc tagtatgtc aataaagcaa atacttactg 2520
ttttgtttct attaatgatt cccaaacctt gttgcaaagt tttgcattgg catctttgga 2580
tttcagtctt gatgtttgtt ctatcagact taacctttta tttcctgtcc ttccttgaaa 2640
ttgctgattg ttctgctccc tctacagata tttatatcaa ttctacagc tttcccctgc 2700
catccctgaa ctctttctag ccctttttaga ttttggcact gtgaaacccc tgctggaaac 2760
ctgagtgacc ctccctcccc accaagagtc cacagacctt tcatctttca cgaacttgat 2820
cctgttagca ggtggttaata ccattgggtgc tgtgacacta acagtcattg agaggtggga 2880
ggaagtcctt tttccttgga ctggtatctt ttcaactatt gttttatcct gtctttgggg 2940
gcaatgtgtc aaaagtcccc tcaggaatct cacttaaatt tacagaaaga ggtgagctgt 3000
tctaaagttt cctttgtata ggagtatgct caactgaaga aagtgtctat attggaacta 3060
gttaaaccctc agagttaaaa agctactgat aaactgaaga tctgtggact ccatttaaaa 3120
gggtcatttg aaagcttcag tctcggaaca tgacctttag tctgtggact ccatttaaaa 3180
ataggtatga ataatgatg taagaatgta atggggaaga actgccctgc ctgccatct 3240
cagagccata aggtcatctt tgctagagct atttttacct atgtatttat cgttcttgat 3300
cataagccgc ttattttatat catgtatctc taaggaccta aaagcacttt atgtagtttt 3360
taattaatct taagatctgg ttacggtaac taaaagcctg tctgccaaat ccagtggaaa 3420
caagtgcata gatgtgaatt ggttttttag ggcccactt cccaattcat taggtatgac 3480
tgtggaaata cagacaagga cttagttgat attttgggct tggggcagtg agggcttagg 3540
acaccccaag tggtttgagg aaggaggagg gagtgggtggg tttatagggg agggaggagg 3600
aggttggtcta agtgctgact ggctacgtag ttcgggcaaa tctccaaaaa gggaaaggga 3660
ggatttgctt agaaggatgg ggctcccagt gactactttt tgacttctgt ttgtcttacg 3720
cttctctcag ggaaaaacat gcagtcctct agtgtttcat gtacattctg tgggggggtga 3780
acaccttggt tctggttaaa cagctgtact tttgatagct gtgccaggaa ggggttaggac 3840
caactacaaa ttaatgttgg ttgtcaaatg tagtgtgttt ccctaacttt ctgtttttcc 3900
tgagaaaaaa aaataaatct tttattcaaa taaa 3934

```

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 19

gccaaacatt gccagtcgcc

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 20

agccaaaagt cgccctcccg

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 21

ctcgtaccog tccagtcct

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 22

tggtattacc agattcccg

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 23

ttggctttgt gtccttggcg

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 24

gagagtcaca atcctgcccc

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 25

aaagccagca gcacattcct

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 26

cctcttgcca cttgcttttc

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 27

cacaggtcac tggcattctt

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 28

aagaatcatg gaaccaagcc

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 29

ctctcaatcc caggttttca

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 30

ggtcaaattg aaggaactca

20

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 31

caaattgtctc tccatccacc

20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 32
aaatccaaag atgccaatgc 20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 33
cagtgcacaa atctaaaagg 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 34
cttctctcca cctctcaatg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 35
ggcagttctt cccattaca 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 36
atttggcaga caggctttta 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: antisense sequence

<400> 37
tagaccacct gcctcctcct

20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 38
gtcctaaccc ttcttggtcac

20

<210> 39
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic peptide

<400> 39
Asp Glu Val Asp
1

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense sequence

<400> 40
tgggtctggt ttctctgtcg

20